Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes
Authors' conclusion
These observations support additional prospective studies evaluating ATG in stage 2 type 1 diabetes.
Study context
- Population
- Children aged 5–14 years with stage 2 T1D
- Participants
- 6 children
- Outcome
- Remained diabetes free (no progression to stage 3 T1D)
- Follow-up
- 1.5, 3, and 4 years
Methodological detailsoff-label, Follow-up 18-48 months
- Off-label
- Follow-up 18-48 months
Main finding
As reported in the abstract
Remained diabetes free
3
50%
Observational data: associations, not effects.
Further findings
Disease progressors 18 months posttreatment: HbA1c, TIR, insulin requirements, 90-min mixed-meal C-peptide · Eighteen months posttreatment
- HbA1c (near-normal)
- 5.1% [32 mmol/mol], 5.6% [38 mmol/mol], and 5.3% [34 mmol/mol]
- TIR
- 93%, 88%, and 98%
- Insulin requirements (low)
- 0.17, 0.18, and 0.34 units/kg/day
- C-peptide 90 min after mixed meal (robust)
- 1.3 ng/dL, 2.3 ng/dL, and 1.4 ng/dL
Original publication
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes. Diabetes Care. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →